论文部分内容阅读
体外药效学研究表明 ,利福布汀对鸟分枝杆菌 -胞内分枝杆菌复合体 (MAC)、结核分枝杆菌、麻风分枝杆菌和其它非典型分枝杆菌的最低抑菌浓度低于利福平 ,且具有抗生素后效应 ;对金黄色葡萄球菌、表皮葡萄球菌和酿脓链球菌也有很强抗菌活性。利福布汀极强的膜透过能力使其具有优异的胞内杀菌活性 ;动物体内实验表明利福布汀对 MAC和结核分枝杆菌感染具有良好疗效。利福布汀口服吸收生物利用度较低 ,但组织分布广泛 ,具有肝药酶诱导作用。临床治疗 MAC和结核分枝杆菌感染具有与利福平相同或更好的疗效 ,但耐药发生率更低。利福布汀对治疗 MAC和多重耐药结核分枝杆菌感染具有临床应用潜力
In vitro pharmacodynamic studies have shown that rifabutin has a low minimum inhibitory concentration (MIC) against Mycobacterium avium - M. intracellulare complex (MAC), M. tuberculosis, M. leprae and other atypical mycobacteria In rifampin, and has antibiotic effects; Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pyogenes also have strong antibacterial activity. Rifabutin has excellent membrane permeability and excellent intracellular bactericidal activity. In vivo experiments in animals show that rifabutin has a good effect on MAC and Mycobacterium tuberculosis infection. Rifabutin oral absorption of bioavailability is low, but the organization is widely distributed, with hepatic drug induced. Clinical treatment of MAC and Mycobacterium tuberculosis infection with rifampicin with the same or better curative effect, but the incidence of drug resistance is lower. Rifabutin is clinically useful for the treatment of MAC and multidrug-resistant Mycobacterium tuberculosis infections